Am J Gastroenterol

1. LOUISSAINT J, Vargas HE
   Picture Perfect: Artificial Intelligence in the Management of Hepatic Encephalopathy.
   Am J Gastroenterol. 2024 Feb 16. doi: 10.14309/ajg.0000000000002659.
   

   >> Share

   
   

   
   BMC Cancer

2. HITCHCOCK KE, Miller ED, Shi Q, Dixon JG, et al
   Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (
   BMC Cancer. 2024;24:201.
   

   >> Share

   
   
3. TAO S, Cui D, Cheng H, Liu X, et al
   High expression of TBRG4 in relation to unfavorable outcome and cell ferroptosis in hepatocellular carcinoma.
   BMC Cancer. 2024;24:194.
   

   >> Share

   
   
4. HU R, Xu J, Wang H, Wang J, et al
   Impact of preoperative transcatheter arterial chemoembolization (TACE) on postoperative long-term survival in patients with nonsmall hepatocellular carcinoma: a propensity score matching analysis.
   BMC Cancer. 2024;24:190.
   

   >> Share

   
   

   
   BMC Gastroenterol

5. CHE Y, Tang R, Zhang H, Yang M, et al
   Development of a prediction model for predicting the prevalence of nonalcoholic fatty liver disease in Chinese nurses: the first-year follow data of a web-based ambispective cohort study.
   BMC Gastroenterol. 2024;24:72.
   

   >> Share

   
   
6. HARI A, Stabuc B
   Possible use of 2D shear wave liver elastography in new-onset ascites evaluation.
   BMC Gastroenterol. 2024;24:68.
   

   >> Share

   
   

   
   Clin Res Hepatol Gastroenterol

7. OBADIA MA, Woimant F, Tuppin P, Debray D, et al
   Reply to "Epidemiology, treatment and burden of Wilson disease in France: A 10-year analysis of the National health insurance database".
   Clin Res Hepatol Gastroenterol. 2024;48:102265.
   

   >> Share

   
   
8. XIE C, Liu K, Xie Y, Liu S, et al
   Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease.
   Clin Res Hepatol Gastroenterol. 2024;48:102264.
   

   >> Share

   
   
9. GUO J, Shi L, Sun Y
   Association of composite dietary antioxidant index and muscle mass in individuals with metabolic associated fatty liver disease.
   Clin Res Hepatol Gastroenterol. 2024;48:102284.
   

   >> Share

   
   
10. HE Q, Xiong Y, Xia P, Yang X, et al
    Predicting cancer-specific mortality in T1/2 hepatocellular carcinoma after radiofrequency ablation by competing risk nomogram: A population-based analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102283.
    

    >> Share

    
    
11. MEJAIT A, Roux C, Soret M, Larrey E, et al
    Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival.
    Clin Res Hepatol Gastroenterol. 2024;48:102282.
    

    >> Share

    
    
12. QI X, Liu L
    The regulatory effect of lncRNA LINC00943 on the progression of hepatocellular carcinoma and its relationship with clinicopathological features.
    Clin Res Hepatol Gastroenterol. 2024;48:102273.
    

    >> Share

    
    

    
    Dig Dis Sci

13. MUKUND A, Aravind A, Jindal A, Tevethia HV, et al
    Predictors and Outcomes of Post-transjugular Intrahepatic Portosystemic Shunt Liver Failure in Patients with Cirrhosis.
    Dig Dis Sci. 2024 Feb 10. doi: 10.1007/s10620-023-08256.
    

    >> Share

    
    
14. ARE VS, Gromski MA, Akisik F, Vilar-Gomez E, et al
    Primary Sclerosing Cholangitis Limited to Intrahepatic Bile Ducts Has Distinctly Better Prognosis.
    Dig Dis Sci. 2024 Feb 12. doi: 10.1007/s10620-023-08260.
    

    >> Share

    
    
15. YE N, Shi X, Gao J, Dong R, et al
    Exosomes from Intrahepatic Cholestasis of Pregnancy Induce Cell Apoptosis Through the miRNA-6891-5p/YWHAE Pathway.
    Dig Dis Sci. 2024 Feb 15. doi: 10.1007/s10620-023-08265.
    

    >> Share

    
    
16. SOHAL A, Kohli I, Chaudhry H, Singh I, et al
    Vaccine-Preventable Illness Leads to Adverse Outcomes in Liver Transplant Recipients.
    Dig Dis Sci. 2023 Nov 29. doi: 10.1007/s10620-023-08202.
    

    >> Share

    
    
17. BEHARI J, Bradley A, Townsend K, Becich MJ, et al
    Limitations of Noninvasive Tests-Based Population-Level Risk Stratification Strategy for Nonalcoholic Fatty Liver Disease.
    Dig Dis Sci. 2024;69:370-383.
    

    >> Share

    
    
18. FIGUEROA G, Castaneda S, McLean H, Dukandar J, et al
    Low Health Literacy, Lack of Knowledge, and Self-Control Hinder Healthy Lifestyles in Diverse Patients with Steatotic Liver Disease.
    Dig Dis Sci. 2024;69:384-398.
    

    >> Share

    
    
19. WAJSBROT NB, Leite NC, Franca PHC, Cardoso CRL, et al
    Parental History of Type 2 Diabetes Mellitus and PNPLA3 Polymorphism Increase the Risk of Severe Stages of Nonalcoholic Fatty Liver Disease.
    Dig Dis Sci. 2024;69:634-642.
    

    >> Share

    
    
20. ASHKTORAB H, Challa SR, Singh G, Nanduri S, et al
    Gastrointestinal Manifestations and Their Association with Neurologic and Sleep Problems in Long COVID-19 Minority Patients: A Prospective Follow-Up Study.
    Dig Dis Sci. 2024;69:562-569.
    

    >> Share

    
    
21. ZEREM E, Denjagic Basic M, Kurtcehajic A, Zerem D, et al
    Indications for the Use of Endoscopic Ultrasound-Guided Liver Biopsy in Patients with Liver Fibrosis.
    Dig Dis Sci. 2024;69:643-644.
    

    >> Share

    
    

    
    Gut

22. KEATING CR, Calvisi DF, Qiu W
    High-fat diet-induced AKT-palmitoylation in hepatocellular carcinoma: a breakthrough mechanistic investigation.
    Gut. 2024 Feb 9:gutjnl-2023-331857. doi: 10.1136/gutjnl-2023-331857.
    

    >> Share

    
    

    
    Hepatology

23. 
    Hepatology Highlights.
    Hepatology. 2024;79:255-256.
    

    >> Share

    
    
24. EHRENBAUER AF, Egge JFM, Gabriel MM, Tiede A, et al
    Comparison of six tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome - A prospective, observational study.
    Hepatology. 2024 Feb 13. doi: 10.1097/HEP.0000000000000770.
    

    >> Share

    
    
25. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    

    >> Share

    
    
26. 
    Erratum: An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
    Hepatology. 2024;79:E105.
    

    >> Share

    
    
27. ZHU M, Liu Z, Chen S, Luo Z, et al
    Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000776.
    

    >> Share

    
    
28. AGRAWAL D, Ariga KK
    Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000789.
    

    >> Share

    
    
29. ALLEGRETTI AS, Patidar KR, Ma AT, Cullaro G, et al
    From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000790.
    

    >> Share

    
    

    
    Indian J Gastroenterol

30. PATIDAR Y, Mittal K, Patel RK, Thomas SS, et al
    Liver volumetry in cirrhotic patients with or without hepatocellular carcinoma: Its correlation with Child-Pugh, model for end-stage liver diseases and indocyanine green dye test.
    Indian J Gastroenterol. 2024 Feb 13. doi: 10.1007/s12664-023-01490.
    

    >> Share

    
    

    
    J Gastroenterol Hepatol

31. JI PX, Chen YX, Ni XX, Miao Q, et al
    Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:369-380.
    

    >> Share

    
    

    
    J Hepatol

32. DE VILLE DE GOYET J
    Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding: Comment on:Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period. Spada M,
    J Hepatol. 2024 Feb 12:S0168-8278(24)00126-0. doi: 10.1016/j.jhep.2024.
    

    >> Share

    
    
33. YANG H, Jang JW
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!'.
    J Hepatol. 2024 Feb 10:S0168-8278(24)00123-5. doi: 10.1016/j.jhep.2024.
    

    >> Share

    
    
34. ARTRU F, Reiberger T
    One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis.
    J Hepatol. 2024 Feb 8:S0168-8278(24)00118-1. doi: 10.1016/j.jhep.2024.
    

    >> Share

    
    
35. ALLWEISS L, Volmari A, Suri V, Wallin JJ, et al
    Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
    J Hepatol. 2024 Feb 8:S0168-8278(24)00114-4. doi: 10.1016/j.jhep.2024.
    

    >> Share

    
    
36. SOIN A, Lesurtel M, Clavien PA
    To the editor: Reply to the letter by Liu et al. entitled "Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis".
    J Hepatol. 2024 Feb 8:S0168-8278(24)00101-6. doi: 10.1016/j.jhep.2024.
    

    >> Share

    
    
37. HUANG CH, Tsai MH, Lin CY
    Identifying the pivotal role of non-acute decompensation as a precursor to acute decompensation in cirrhosis.
    J Hepatol. 2024 Feb 7:S0168-8278(24)00119-3. doi: 10.1016/j.jhep.2024.
    

    >> Share

    
    

    
    N Engl J Med

38. HARRISON SA, Bedossa P, Guy CD, Schattenberg JM, et al
    A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:497-509.
    

    >> Share

    
    

    
    PLoS One

39. LIU Z, Shao Y, Duan X
    Genetic link between primary biliary cholangitis and connective tissue diseases in European populations: A two-sample Mendelian randomization study.
    PLoS One. 2024;19:e0298225.
    

    >> Share

    
    
40. MATSUO M, Kanbe A, Noguchi K, Niwa A, et al
    Time-course analysis of liver and serum galectin-3 in acute liver injury after alpha-galactosylceramide injection.
    PLoS One. 2024;19:e0298284.
    

    >> Share

    
    

    
    Pol J Radiol

41. SALAHSHOUR F, Khameneh AG, Amirkhiz GDH, Yazdi NA, et al
    Texture analysis on routine MRI sequences to differentiate between focal nodular hyperplasia and hepatocellular adenoma.
    Pol J Radiol. 2023;88:e589-e596.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

42. ALBUQUERQUE J, Lin YM, Paolucci I, O'Connor CS, et al
    Incidental Ring-hyperenhancing Liver Micronodules at CT Hepatic Arteriography-guided Percutaneous Thermal Ablation of Colorectal Liver Metastases.
    Radiol Imaging Cancer. 2024;6:e230099.
    

    >> Share

    
    

    
    Radiology

43. GEMMETE JJ
    Partial Cryoablation and Matrix Metalloproteinase Inhibition May Be a Possible Treatment Option for Hepatocellular Carcinoma.
    Radiology. 2024;310:e240015.
    

    >> Share

    
    
44. SHEWAREGA A, Santana JG, Nam D, Berz A, et al
    Effect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8(+) T-Cell Infiltration in Murine Hepatocellular Carcinoma.
    Radiology. 2024;310:e232365.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share